Cardiol Therapeutics (TSE:CRDL) Rating Reiterated by HC Wainwright

Cardiol Therapeutics (TSE:CRDL)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Monday, BayStreet.CA reports.

Cardiol Therapeutics Trading Up 2.0 %

Shares of CRDL opened at C$2.49 on Monday. Cardiol Therapeutics has a twelve month low of C$0.74 and a twelve month high of C$2.94. The company has a market cap of C$162.12 million, a P/E ratio of -5.79 and a beta of 0.75. The company has a current ratio of 5.29, a quick ratio of 6.84 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is C$2.28 and its 200-day simple moving average is C$1.61.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.